Form 4: Director David P. Bonita Receives Option Grant at Prelude

Director David P. Bonita was granted 38,000 stock options in Prelude Therapeutics Inc. as part of a standard compensation arrangement.

Summary

• Director David P. Bonita received a grant of 38,000 stock options for Prelude Therapeutics Inc. (PRLD) common stock.
• The options have an exercise price of $3.94 per share.
• The grant date is June 9, 2026, with an expiration date of June 8, 2036.
• The reporting person is obligated to transfer the economic benefit of these securities to OrbiMed Advisors LLC and related entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant change in company strategy or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The reporting person does not retain the economic benefit of the options, as they are contractually obligated to transfer them to OrbiMed entities.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $3.94 exercise price.

Future Outlook

The options vest on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors representing institutional investors like OrbiMed are standard practice in the biotechnology sector to ensure board alignment with corporate governance and long-term development milestones.

Comparison to Industry Standards

• The vesting schedule of one year or the next annual meeting is consistent with standard director compensation practices for small-cap biotech firms.

Related Party Transactions

• The reporting person is contractually obligated to transfer the economic benefit of these options to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation grant.

Next Steps

• Vesting of options upon the earlier of the next annual stockholder meeting or June 9, 2027.

Key Dates

Keywords

Prelude Therapeutics, PRLD, Form 4, Insider Trading, Stock Options, OrbiMed